Autopsy report · NCT02439957

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

“Study terminated early due to results from another CMX001 study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 5 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Jazz Pharmaceuticals

Sponsor type

Industry

Conditions

Cytomegalovirus Disease; Kidney Transplant Infection

Interventions

Brincidofovir; Valganciclovir

Participants

6

Sites

3

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.